The Effect of Treatment in Patients with Chronic Myelogenous Leukemia
Authors: JEROME B. BLOCK
Journal: Annals of Internal Medicine (1963)

Article1 November 1963The Effect of Treatment in Patients with Chronic Myelogenous LeukemiaBiochemical StudiesJEROME B. BLOCK, M.D., PAUL P. CARBONE, M.D., JOOST J. OPPENHEIM, M.D., MIL FREI III, M.D.JEROME B. BLOCK, M.D.Search for more papers by this author, PAUL P. CARBONE, M.D.Search for more papers by this author, JOOST J. OPPENHEIM, M.D.Search for more papers by this author, MIL FREI III, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-59-5-629 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe circulating leukocytes of patients with chronic myelogenous leukemia (CML) have decreased or absent leukocyte alkaline phosphatase (LAP) activity (1-3). Recently, it has been shown that these leukocytes have a high intracellular hydrogen ion concentration (4, 5) and diminished leukocyte acid excretion when compared with leukocytes from patients without hematologic disease (5-7). The relative effects of several chemotherapeutic agents on the magnitude and duration of response of hematologic and cytogenetic abnormalities in patients with CML have been presented in the preceding paper by Carbone et al. (8) in this issue of the ANNALS. The present report describes the effects of...References1. WACHESTEIN M: Alkaline phosphatase activity in blood and bone marrow cells. J. Lab. Clin. Med. 31: 1, 1946. MedlineGoogle Scholar2. VALENTINEBECK WNWS: Biochemical studies on leukocytes. I. Phosphatase activity in health, leukocytosis and myelocytic leukemia. J. Lab. Clin. Med. 38: 38, 1951. Google Scholar3. WILTSHOWMOLONEY EWC: Histochemical and biochemical studies on leukocyte alkaline phosphatase activity. Blood 10: 1120, 1955. CrossrefMedlineGoogle Scholar4. BLOCK JB: Intracellular pH of leukocytes. Proc. Am. Ass. Cancer Res. 3: 305, 1962. Google Scholar5. BLOCKRALL JBDP: Measurements of leukocyte intracellular pH with C14-labelled 5, 5-dimethyl-2, 4-oxazolidinedione. Submitted for publication. Google Scholar6. BECKVALENTINE WSWN: The anaerobic carbohydrate metabolism of leukocytes in health and leukemia. Cancer Res. 12: 818, 1952. MedlineGoogle Scholar7. MARTINMCKINNEY SPGR: The metabolism of human polymorphonuclear leukocytes. Ann. N.Y. Acad. Sci. 59: 996, 1955. CrossrefMedlineGoogle Scholar8. CARBONETJIOWHANGBLOCKKREMERFREI PPJMJJBWBE: The effect of treatment in patients with chronic myelogenous leukemia: Hematologic and cytogenetic studies. Ann. Intern. Med. 59: 3, 0000. Google Scholar9. PEACOCKBRECHERHIGHSMITH ACGE: A simplified procedure for quantitative measurement of alkaline phosphatase in white blood cells. Am. J. Clin. Path. 29: 80, 1958. CrossrefMedlineGoogle Scholar10. GOMORI G: Histochemical demonstration of phosphatase in tissue sections. Proc. Soc. Exp. Biol. Med. 42: 23, 1939. CrossrefGoogle Scholar11. WADDELLBUTLER WSTC: Calculations of intracellular pH from the distribution of 5,5-dimethyl-2, 4-oxazolidinedione (DMO) application to skeletal muscle of the dog. J. Clin. Invest. 38: 720, 1959. CrossrefMedlineGoogle Scholar12. IRVINESAUNDERSMILNECRAWFORD ROSSMDNA: Gradients of potassium and hydrogen ion in potassium deficient voluntary muscle. Clin. Sci. 20: 1, 1961. MedlineGoogle Scholar13. MORSEBRONSONKLIMANFREIREICHCARBONE EEWBAEJPP: Repeat plasmophoresis of donors with chronic leukemia as a source of granulocytes. Manuscript in preparation. Google Scholar14. FALLONFREIDAVIDSONTRIERBURKE HJEJDJSD: Leukocyte preparations from human blood: Evaluation of their morphologic and metabolic state. J. Lab. Clin. Med. 59: 779, 1962. MedlineGoogle Scholar15. VALENTINEFOLLETTESOLOMONREYNOLDS WNJMDHJ: Biochemical and enzymatic characteristics of normal and leukemic leukcocytes, in The Leukemias. Etiology, Pathophysiology, and Treatment. Henry Ford Hospital, International Symposium, edited by REBUCK, J., Academic Press, Inc., New York, 1957. Google Scholar16. XEFTERISMITUSMEDNICOFFDAMESHEK EWJIBW: Leukocyte alkaline phosphatase in busulfan induced remissions of chronic granulocytic leukemia. Blood 18: 202, 1961. CrossrefMedlineGoogle Scholar17. KENNYMOLONEY JJWC: Leukocytic alkaline phosphatase: Behavior during prolonged incubation and infection in normal and leukemic leukocytes. Blood 12: 295, 1957. CrossrefMedlineGoogle Scholar18. KAPLOW LS: A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase in smears of blood and marrow. Blood 10: 1023, 1955. CrossrefMedlineGoogle Scholar19. WHANGCARBONEBLOCKFREI JPPJBE: Unpublished observations. Google Scholar20. TRUBOWITZKIRMANMASEK SDB: The leukocyte alkaline phosphatase in mongolism. Lancet 2: 486, 1962. CrossrefMedlineGoogle Scholar21. KINGGILLISBAIKIE MJEMAG: The polymorphalkaline phosphatase in mongolism. Lancet 2: 661, 1962. CrossrefGoogle Scholar22. FITZGERALDADAMSGUNZ PHAW: Chronic granulocytic leukemia and the Philadelphia chromosome. Blood 21: 183, 1963. CrossrefMedlineGoogle Scholar23. HUGULEYGRIZZLERUNDLESBELLCORLEYFROMMEYERGREENBERGHAMMACKHERIONJAMESLARSENLOEBLEONEPALMERWILSON CMJWRWNCCWBBGWJCGWWEVLAJGSJ: Comparison of 6-mercaptopurine and busulfant in chronic myelogenous leukemia. Blood 21: 89, 1963. CrossrefGoogle Scholar24. ELLISONBURCHENAL RRJH: Treatment of chronic granulocytic leukemia with the 6-substituted purines 6-mercaptopurine, thioguanine and 6-chloropurine. Clin. Pharmacol. Ther. 1: 631, 1960. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bethesda, MarylandFrom the Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.Requests for reprints should be addressed to Paul P. Carbone, M.D., Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda 14, Maryland. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByChronic Myelogenous LeukemiaFUNCTIONAL AND BIOCHEMICAL PHENOTYPE IN RELATION TO CELLULAR AGE OF DIFFERENTIATED NEUTROPHILS IN CHRONIC MYELOID LEUKAEMIAChronic Myelogenous Leukemia — New ConceptsLeukocyte alkaline phosphataseProliferative Disorders of the T-Cell SeriesDie chronische myeloische LeukämieThe Clinical Features of Chronic Granulocytic LeukaemiaThe Treatment of Chronic Granulocytic LeukaemiaChronic Granulocytic LeukemiaThe Leukemias and LymphomasNeutrophil Function in Chronic Granulocytic Leukaemia before and after Busulphan TreatmentThe Spectrum of Myeloproliferative DisordersUnfavorable Signs in Patients with Chronic Myelocytic LeukemiaATHANASIOS THEOLOGIDES, M.D., Ph.D., F.A.C.P.Leukocyte Alkaline Phosphatase in DiseaseThe myeloproliferative disordersLEUKOCYTE ALKALINE PHOSPHATASE IN CHRONIC GRANULOCYTIC LEUKEMIA OF CHILDHOODLEUKOCYTE ALKALINE PHOSPHATASE IN THE 21-TRISOMY (DOWN'S) SYNDROMLEUKOCYTE ALKALINE PHOSPHATASE IN CHRONIC GRANULOCYTIC LEUKEMIA OF CHILDHOODLEUKOCYTE ALKALINE PHOSPHATASE IN THE 21-TRISOMY (DOWN'S) SYNDROMEnzyme Abnormality in Human LeukaemiaAlkaline PhosphataseSOLOMON POSEN, M.D., F.R.A.C.P.Etude clinique et cytogénétique de 21 patients atteints de leucémie myéloïde chroniqueLeukocyte Alkaline Phosphatase: Electrophoretic Variants Associated with Chronic Myelogenous LeukemiaAdhesiveness to Glass and Phagocytic Activity of Neutrophilic Leukocytes in Myeloproliferative DiseasesPersistent Mitosis of Transfused Homologous Leukocytes in Children Receiving Antileukemic Therapy 1 November 1963Volume 59, Issue 5_Part_1Page: 629-636KeywordsAttentionCancer treatmentChemotherapeutic agentsChronic myelocytic leukemiaChronic myelogenous leukemiaCytogeneticsExcretionPatientsPhosphatases Issue Published: 1 November 1963 PDF DownloadLoading ...